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Opening of the permeability transition pore (PTP), a high-conductance mitochondrial channel, causes mitochondrial dysfunction with Ca2+
deregulation, ATP depletion, release of pyridine nucleotides and of mitochondrial apoptogenic proteins. Despite major efforts, the molecular
nature of the PTP remains elusive. A compound library screening led to the identification of a novel high affinity PTP inhibitor (Ro 68-3400),
which labeled a ∼32 kDa protein that was identified as isoform 1 of the voltage-dependent anion channel (VDAC1) [A.M. Cesura, E. Pinard, R.
Schubenel, V. Goetschy, A. Friedlein, H. Langen, P. Polcic, M.A. Forte, P. Bernardi, J.A. Kemp, The voltage-dependent anion channel is the target
for a new class of inhibitors of the mitochondrial permeability transition pore. J. Biol. Chem. 278 (2003) 49812–49818]. In order to assess the role
of VDAC1 in PTP formation and activity, we have studied the properties of mitochondria from VDAC1−/− mice. The basic properties of the PTP in
VDAC1−/− mitochondria were indistinguishable from those of strain-matched mitochondria from wild-type CD1 mice, including inhibition by Ro
68-3400, which labeled identical proteins of 32 kDa in both wild-type and VDAC1−/− mitochondria. The labeled protein could be separated from
all VDAC isoforms. While these results do not allow to exclude that VDAC is part of the PTP, they suggest that VDAC is not the target for PTP
inhibition by Ro 68-3400.
© 2006 Elsevier B.V. All rights reserved.Keywords: Mitochondria; Permeability transition; VDAC11. Introduction
The mitochondrial permeability transition pore (PTP) plays
an important role in Ca2+ homeostasis, bioenergetics and cell
death. Although the role of the PTP in pathophysiology in vivo
has been firmly established [1–3], and despite detailed
functional characterization [4], the molecular components
forming the PTP remain undefined [5].
Early studies demonstrated that the permeability transition
induced by sulfhydryl reagents is not observed in mitoplasts,Abbreviations: CRC, Ca2+ retention capacity; CsA, cyclosporin A; CyP-D,
cyclophilin D; FCCP, carbonylcyanide-p-trifluoromethoxyphenyl hydrazone;
NEM, N-ethylmaleimide; PhAsO, phenylarsine oxide; PBS, phosphate buffered
saline; PTP, permeability transition pore; Ro 68-3400, spiro[cyclopentane-1,5′-
[5H]dibenzo[a,d]cyclohepten]-2-one,19′,11′-dihydro-3-methylene; Ub, ubiqui-
none; VDAC, voltage-dependent anion channel
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doi:10.1016/j.bbabio.2006.02.007suggesting that inner membrane permeability changes require
the outer mitochondrial membrane as well [6]. Several lines of
evidence suggest that the outer membrane protein involved in
PTP formation may be VDAC: (i) purified VDAC incorporated
into planar phospholipid bilayers forms channels with a pore
diameter of 2.5–3.0 nM whose electrophysiological properties
are strikingly similar to those of the PTP [7,8]; (ii) the VDAC
channel properties change when activity is assessed in the
presence of NADH, Ca2+ or glutamate [9–11], or after binding
of hexokinase II [12,13], conditions that also modulate the
activity of the PTP [14–16]; (iii) chromatography of mitochon-
drial extracts on a cyclophilin D (CyP-D) affinity matrix
allowed purification of VDAC and the adenine nucleotide
translocase, which in the presence of CyP-D (the mitochondrial
receptor for cyclosporin A, CsA) catalyzed CsA-sensitive
permeabilization of liposomes to solutes [17].
The idea that VDAC is a component of the PTP has been
considerably reinforced by a recent study where a chemical
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of rat liver mitochondria. A novel compound, spiro[cyclopen-
tane-1,5′-[5H]dibenzo[a,d]cyclohepten]-2-one,19′,11′-dihy-
dro-3-methylene (Ro 68-3400) was identified that inhibits the
PTP with high affinity [18] and labeling of mitochondria with
[3H]Ro 68-3400 revealed prominent reactivity of a membrane
protein of ∼32 kDa [18]. The tracer was competitively
displaced by unlabeled Ro 68-3400 and partial purification of
the labeled protein led to identification of isoform 1 of the
voltage-dependent anion channel (VDAC1) as the mitochon-
drial target of Ro 68-3400 [18].
In order to further test whether VDAC1 is a component of
the PTP, we have studied the properties of the PTP in
mitochondria from VDAC1−/− and wild-type, strain-matched
mice.
2. Materials and methods
2.1. Compounds and chemicals
Ro 68-3400 was prepared at Hoffmann-La Roche Ltd., Basel, Switzerland.
[3H]Ro 68-3400 (65 Ci/mmol, 1 Ci=37 Mbq) was kindly prepared by Dr.
Thomas Hartung (Hoffmann-La Roche Ltd., Basel, Switzerland). Carbonylcya-
nide-p-trifluoromethoxyphenyl hydrazone (FCCP), CsA, N-ethylmaleimide
(NEM), phenylarsine oxide (PhAsO) and ubiquinone (Ub) 0 were from Sigma.
2.2. Animals
VDAC1-deficient mice were generated by homologous recombination in
embryonic stem cells followed by blastocyst microinjection, as previously
described [19,20]. The engineered mutation deletes exons 2–5, including the
start codon, creating a null allele. Because of partial embryonic lethality in
certain genetic backgrounds, the VDAC1 mutation was backcrossed onto the
outbred strain CD1 and the resulting mice intercrossed to create VDAC1-
deficient and wildtype littermate control mice. Genotyping was carried out by
PCR, as described [21]. Mice were maintained and treated in accordance with an
institutionally approved animal protocol.
2.3. Preparation of mouse liver mitochondria
Mitochondria were isolated from the livers of wild-type CD1 and VDAC1−/−
mice exactly as described previously for rat liver mitochondria [22] except that
10 ml of isolation medium per liver were used.
2.4. Mitochondrial swelling
Mitochondrial volume changes were determined from the changes in
absorption at 545 nm with a Perkin Elmer λ10 spectrophotometer equipped with
magnetic stirring and thermostatic control. The incubation conditions are
described in the figure legends.
2.5. Western blot analysis
Eighty micrograms of total protein were separated on 12% SDS-
polyacrylamide gels. The separated proteins were transferred to polyvinylidene
difluoride membranes. Membranes were blocked in a solution of 500 mMNaCl,
20 mM Tris–HCl, 0.3% Tween 20, pH 7.4 containing 5% (v/v) skimmed milk
for 1 h at room temperature and then incubated with a commercial monoclonal
antibody specific for VDAC1 (mAb1, Calbiochem) [23], or polyclonal
antibodies specific for VDAC2 and VDAC3 as described in [20]. The secondary
antibody used was peroxidase-conjugated anti-mouse IgG for mAb1 (1:5000
dilution) and anti-chicken IgG (1:10,000 dilution) for the polyclonal antibodies
specific for VDAC2 and VDAC3, respectively. The membranes were developed
using an ECL reaction and exposed to Kodak X-Omat films for 1–10 min.2.6. Affinity labeling of mitochondria
Mitochondria (50–80 μg protein per sample) were incubated in the presence
of 10 nM [3H]Ro 68-3400 in a final volume of 400 μl in 150 mM NaCl, 10 mM
Pi pH 7.4 (phosphate buffered saline, PBS). After incubation for 15 min at 25
°C, samples were centrifuged at 10,000×g. Samples were solubilized in sample
buffer containing β-mercaptoethanol (30 min at 37 °C) and subjected to SDS-
polyacrylamide gel-electrophoresis (PAGE) on Tris–glycine mini-gels (12%
polyacrylamide). After Coomassie Blue staining, gels were processed for
fluorography by soaking in Amplify™ (Amersham Biosciences) for 1 h, drying
and exposure to X-ray BioMax MS film with BioMax MS intensifying screens
at −80 °C for the appropriate times.
2.7. Hydroxyapatite chromatography
Mitochondria (about 5 mg protein in 5 ml) were labeled as described above
with 10 nM [3H]Ro 68-3400 for 15 min at 25 °C, and all the following steps
were carried out at 4 °C unless otherwise stated. After centrifugation, the labeled
mitochondria were solubilized in 5 mM Tris–HCl pH 7.0, 1 mM EDTA. The
vial with the extract was kept in an ice-water bath and sonicated at 35 W with a
micro tip in a Fisher Sonic 300 instrument until the turbidity of the suspension
disappeared. This suspension was centrifuged at 7000×g to eliminate unbroken
mitochondria and the supernatant was centrifuged at 100,000×g for 20 min. The
resulting pellet was solubilized in 1.2 ml 5 mM Tris–HCl, pH 7.0, 1 mM EDTA,
1% Triton TX-100 (buffer A). After 30 min on ice, the suspension was
centrifuged at 20,000×g for 10 min and the supernatant further processed.
The mitochondrial proteins were fractionated essentially as described in [24]
with the following modifications. The supernatant was filtered through 0.22 μm
filters (Millipore) and applied onto a ceramic hydroxyapatite Type-II 20×0.5 cm
column (Amersham Biosciences Äkta FPLC purifier) equilibrated with buffer A
at 25 °C. The flow rate was set at 0.5 ml buffer A×min−1 and the flowthrough
was collected. Subsequently, a gradient from 100% buffer A to 100% buffer B
(1 M NaCl, 200 mM NaPi, 1% Triton X-100, pH 7.4) was applied. The
radioactive 32 kDa band eluted between 55 and 65% buffer B and relevant
fractions were pooled for further analysis.
Proteins were precipitated by the addition of 4 volumes of ice-cold acetone.
After 12 h at −20 °C, proteins were collected by centrifugation at 20,000×g for
30 min at 4 °C. The supernatants were removed and 20% trichloroacetic acid
was added. After 30 min on ice, the proteins were collected by centrifugation at
20,000×g for 30 min at 4 °C. The supernatants were removed and the pellets
washed with diethylether. After centrifugation at 20,000×g for 30 min at 4 °C,
the pellets were washed with water and the final pellets were dried under
vacuum. The supernatant of the final water wash was checked for radioactivity
and no radioactivity was detected. Proteins were resuspended in standard
Laemmli gel sample buffer and subjected to SDS-PAGE, Western blot analysis
and autoradiography in parallel samples as described above.
3. Results and discussion
We compared the properties of the PTP in mitochondria
from the liver of wild-type CD1 and of VDAC1−/− mice.
PTP opening was monitored as the decrease of absorbance of
the mitochondrial suspension that follows mitochondrial
swelling (Fig. 1). After the addition of a permissive Ca2+
pulse, PTP opening was induced with three different stimuli,
i.e., the protonophore FCCP (traces a, a′), which causes pore
opening through depolarization [25]; PhAsO (traces b, b′),
which causes pore opening through dithiol cross linking [26];
and a relatively high concentration of NEM (c, c′), which
causes pore opening by sensitizing it to oxidants [27]. Mouse
mitochondria readily underwent the expected swelling
response upon the addition of the PTP inducers, and the
rate and extent of swelling (which was fully sensitive to
CsA, results not shown) was indistinguishable in wild-type
Fig. 1. Mitochondrial swelling induced by FCCP, PhAsO and NEM in wild-type
CD1 and VDAC1−/− mouse liver mitochondria. One milligram of mitochondrial
protein from wild-type CD1 (traces a–c) or VDAC−/− (traces a′–c′) mouse liver
was incubated at 25 °C in 2 ml of 0.25 M sucrose, 10 mM Tris–Mops, 1 mM Pi–
Tris, 5 mM glutamate–Tris, 2.5 mM malate–Tris, pH 7.4. Where indicated by
arrows, 40 μM Ca2+ was added followed by 200 nM FCCP, 50 μM PhAsO or
1 mM NEM. Traces shown are representative of at least 3 independent
experiments.
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that the permeability transition can occur in the absence of
VDAC1.
We next tested whether the PTP in VDAC1−/− mitochondria
could be inhibited by CsA, Ub0 and Ro 68-3400 (Fig. 2). The
inhibitory effects of CsA on the PTP is mediated by its
interactions with CyP-D [28–30] through a mechanism that is
clearly distinct from that of Ro 68-3400 [18]. Therefore, the
finding that CsA inhibited the PTP with exactly the same
affinity in wild-type and VDAC1−/− mitochondria was not
surprising (panel A). The unexpected finding was that both
Ub0 and Ro 68-3400, which are presumed to act at the same
site on VDAC1 [18], displayed identical potencies at PTP
inhibition in the VDAC1−/− and wild-type mitochondria
(panels B and C). In order to assess whether PTP inhibition
correlated with reaction of the 32 kDa protein previouslyFig. 2. Inhibition of mitochondrial swelling by CsA, Ub0 and Ro 68-3400 in wild-type
in Fig. 1. One minute after the addition of 40 μM Ca2+, mitochondrial swelling
concentrations of CsA (panel A), Ub0 (panel B) or Ro 68-3400 (panel C) to liver mi
Values on the ordinate refer to the fraction (Φ) of swollen mitochondria after the add
independent experiments.identified by affinity labeling [18], liver mitochondria were
treated with 10 nM [3H]Ro 68-3400 after incubation with
increasing concentrations of unlabeled Ro 68-3400 or Ub0 and
subjected to SDS-PAGE and autoradiography. A radioactive
protein of 32 kDa was detected in both wild-type and
VDAC1−/− mitochondria, whose binding could be competed
by Ro 68-3400 at 10–100 nM and by Ub0 at 10–30 μM (Fig.
3), i.e., the same concentrations of these compounds causing
significant inhibition of the PTP [18,31]. This finding clearly
demonstrates that a protein other than VDAC1, but with
similar electrophoretic mobility, is labeled by [3H]Ro 68-3400
in mitochondria prepared from VDAC1−/− mice. In line with
this result is the fact that Ro 68-3400 had an inhibitory effect
on Ca2+-induced swelling in VDAC1−/− mouse liver mito-
chondria (Fig. 2).
Three genes encode VDAC isoforms in mammals [32] and
each isoform is able to form channels when incorporated into
planar bilayers, albeit with somewhat different characteristics
[33]. A reasonable explanation for the above findings could be
that in the absence of VDAC1 other isoforms of the protein may
take part in PTP formation. A Western blot analysis confirmed
the absence of VDAC1 in liver mitochondria from VDAC1−/−
mice, and demonstrated that identical levels of VDAC2 and
VDAC3 are expressed in wild-type and VDAC1−/− mitochon-
dria. In addition, the levels of protein capable of high-affinity
modification by Ro 68-3400 were identical in VDAC1−/− and
wild-type mitochondria (Fig. 4).
In order to establish whether the Ro 68-3400-reactive
32 kDa species of VDAC1−/− mitochondria was VDAC2 and/
or VDAC3, we labeled mitochondria with 10 nM [3H]Ro 68-
3400 and subjected the membrane fraction to chromatography
on hydroxyapatite after extraction with detergent. As shown in
Fig. 5, panel A, all the 3 VDAC isoforms present in wild-type
mitochondria, as well as VDAC2 and VDAC3 present in
VDAC1−/− mitochondria (lane 1) were recovered in the
flowthrough (lane 2), while none could be found in the
fraction eluting at about 120 mM Pi (lane 3). Quite
unexpectedly, the 32 kDa protein labeled by [3H]Ro 68-
3400 was absent in the VDAC-containing flowthrough
fractions, while it was recovered in the 120 mM Pi-eluted
fraction (Fig. 5, panel B).CD1 and VDAC1−/−mouse liver mitochondria. Experimental conditions were as
was initiated by the addition of 200 nM FCCP in the presence of the stated
tochondria from wild-type CD1 (full circles) or VDAC1−/− (empty circles) mice.
ition of FCCP [see Ref. [36] for details]. Data are the average±S.D. of at least 3
Fig. 5. Fractionation of detergent extracts from wild-type CD1 and VDAC1−/−
mouse liver mitochondria on hydroxyapatite. Mitochondria from wild-type
CD1 and VDAC1−/− mice were labeled with 10 nM [3H]Ro 68-3400, extracted
with detergent and subjected to hydroxyapatite chromatography as described in
Materials and methods. Samples of the total extract (lane 1), the flowthrough
(lane 2) and the fractions eluting at about 120 mM Pi (lane 3) from the
hydroxyapatite column were separated by SDS-PAGE and subjected to
Western blot analysis with specific antibodies against VDAC1, VDAC2 and
VDAC3 (as indicated on the right-hand side of panel A); and fluorography
(panel B, where the ∼32 kDa region is shown).
Fig. 3. Competition of Ro 68-3400 and Ub0 for [
3H]Ro 68-3400 incorporation
into wild-type CD1 and VDAC1−/− mouse liver mitochondria. Liver
mitochondria from wild-type CD1 or VDAC1−/− mice (80 μg protein per
sample) were incubated in a final volume of 400 μl of PBS in the absence of
further additions (first lane in panels A and B) or in the presence of the indicated
concentrations of unlabeled Ro 68-3400 (panel A) or Ub0 (panel B) for 5 min.
Mitochondria were centrifuged at 20,000×g, washed twice with PBS and
labeled with 10 nM [3H]Ro 68-3400 exactly as described in Materials and
methods. Fluorographs of the SDS-PAGE gels in the∼32 kDa region are shown.
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those of Cesura et al., who found the [3H]Ro 68-3400-labeled
species in the flowthrough fraction [18] is not obvious, but
must lie in subtle differences in sample preparation that are
currently under active investigation. Irrespective of the basis
for this discrepancy, our ability to resolve the 32 kDa labeled
species from all VDAC isoforms demonstrates that none of
them can be the target for Ro 68-3400, consistent with the
finding that this compound inhibits equally well the PTP in
wild-type and VDAC1−/− mitochondria. We are currently in
the process of identifying the protein(s) labeled by [3H]Ro
68-3400. So far, MALDI TOF-MS analysis of the labeled
region did not demonstrate the presence of any of the proteins
proposed to be implicated in the PTP, including the adenine
nucleotide translocator.
4. Summary and conclusions
A considerable amount of experimental evidence sug-
gests that outer membrane VDAC may take part in PTPFig. 4. Expression of VDAC isoforms in wild-type CD1 and VDAC1−/− mouse
liver mitochondria. Mitochondria from CD1 (lane 1) and VDAC1−/− mice (lane
2) were separated by SDS-PAGE after labeling with 10 nM [3H]Ro 68-3400 and
subjected to fluorography (panel A) or Western blotting with antibodies specific
for VDAC1, VDAC2 and VDAC3 (panel B).formation [7–17], an issue that was considerably strength-
ened by our identification of VDAC1 as the target for the
high affinity inhibitor Ro 68-3400 [18]. Data in this
manuscript indicate that the properties of the PTP in
VDAC1−/− mitochondria are identical to those of wild-type
mitochondria; and that Ro 68-3400 does not bind to any of
the mouse VDAC isoforms. These results demonstrate the
VDACs are not the mitochondrial receptors for Ro 68-
3400, but do not rule out that VDACs may be part of the
PTP.
Mice missing VDAC1 and VDAC3 are viable but display
isoform-specific phenotypes [34], while the unconditional
elimination of VDAC2 results in embryonic lethality [35].
Thus, as was the case for the present study, the involvement of
specific VDAC isoforms in PTP function will be difficult to
assess in these animals since any VDAC isoform may
potentially compensate for the absence of any other isoform.
The application of more advanced genetic approaches (e.g.,
loxP versions of individual VDAC genes or the use of siRNA)
may allow the generation of reliable data. Until such studies are
available, the involvement of VDAC in PTP formation remains
an open question.
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